NCCN Guidelines for Patients
Rectal Cancer, Version 1.2017
Overview of cancer treatments
Panitumumab is the same type of drug as cetuximab.
However, it does somewhat differ from cetuximab
in its structure. It works much like cetuximab by
attaching to EGFRs and attracting immune cells.
Panitumumab is given by IV infusion over 1 hour
every other week. It may be given with or without
Panitumumab rarely causes infusional reactions.
Common side effects are skin rash and swelling
around the nails. You may get diarrhea, nausea,
and feel tired. Blood magnesium levels may drop.
Rare but serious side effects include lung and eye
The immune system is your body’s natural defense
against infection and disease. The immune system
includes many chemicals and proteins. These
chemicals and proteins are made naturally in your
body. Immunotherapy increases the activity of your
immune system. By doing so, it improves your body’s
ability to find and destroy cancer cells.
T-cells are part of your immune system. One job of
T-cells is to attack cancer cells. PD-L1 is a molecule
that can stop T-cells from doing their job.
Rectal cancers that have dMMR or MSI-H also have
PD-L1 on the cells’ surface. PD-L1 attaches to PD-1
on T-cells. This stops T-cells from attacking cancer
EGFR targeted therapy
Some rectal cancers consist of
cells with too many or overactive
EGFRs. EGFRs trigger growth
signals with cancer cells.
Cetuximab and panitumumab
block EGF from attaching to
EGFR and turning it on.
Copyright © 2017 National Comprehensive Cancer Network